Latest Industry Insights

A receptor (drug target) can shift from a single subunit to a multi-structure in the presence of a ligand (drug compound) – a process known as "oligomerization". Now, using photon excitation microscopy, researchers report that they can uncover the various protein receptor oligomers formed in the absence or presence of different drug candidates that bind to them.

Aided by advances in high-throughput technologies, the metabolomics research field has gained significant traction. We spoke with Baljit Ubhi, Ph.D. from SCIEX, about the recent developments in metabolomics, addressing the increasing focus on the microbiome, how it impacts metabolic disease, and the future directions of research, including "precision nutrition".

Technology Networks recently visited Dresden, Germany, for Lipotype's Lipid Excellence Award press talk, where we gained insights into the past, present and future of lipidomics research.

Recent developments in MS technology have enabled a fourth dimension of analysis: ion mobility separation. The term "4D proteomics" has been created to describe analysis that incorporates all four dimensions. We interviewed two researchers at the forefront of the proteomics field to learn more about how 4D proteomics approaches are enhancing their research.

Technology Networks recently spoke with Professor Jürgen Cox to learn more about the computational software tools his laboratory are developing, and how 4D proteomics workflows enhance research in clinical proteomics.

Technology Networks spoke with Dr Roman Fischer to learn more about the challenges researchers face in the field of clinical proteomics, and how 4D proteomics workflows are enhancing his laboratory's work.

Digitization is a trend threading many disciplines, and lateral flow is no exception. Here, we share insights from Dave Taylor, co-founder and chief operating officer of Bond Digital Health, a UK-based life sciences company that develops app and cloud technology solutions for lateral flow diagnostics.

We recently spoke with Paul Wotton, Ph.D., CEO at Obsidian Therapeutics, to gain his insights on the genetically engineered cell-therapy research area, and to learn how Obsidian Therapeutics' cytoDRiVE platform can increases the specificity and safety of such therapies.

Ion mobility spectrometry (IMS) coupled to mass spectrometry (MS) has witnessed significant growth over the last two decades. To better understand IMS, the benefits this technology provides, and exactly what Waters' new SELECT SERIES CyclicTM IMS offers, we spoke to Emma Marsden-Edwards.

Proteinopathies are diseases that feature misfolded proteins. In the brain, proteinopathies are rife, but research techniques are facing up to the challenge of studying these diseases. We talked to the University of Cambridge’s Tom Scheidt, whose research uses an innovative technique called diffusional sizing to better understand proteins.